DOCSLIB.ORG

A SDHB Malignant Paraganglioma with Dramatic Response To

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A SDHB Malignant Paraganglioma with Dramatic Response To European Journal of Endocrinology (2012) 166 1107–1111 ISSN 0804-4643 CASE REPORT A SDHB malignant paraganglioma with dramatic response to temozolomide–capecitabine Ce´cile Nozie`res1,2, Thomas Walter1,2,5, Marie-Odile Joly3,5, Sophie Giraud2,4, Jean-Yves Scoazec2,3,5, Franc¸oise Borson-Chazot2,5,6, Chantal Simon2,7, Jean-Paul Riou7 and Catherine Lombard-Bohas1,5 1Hospices Civils de Lyon, Hoˆpital Edouard Herriot, Fe´de´ration des Spe´cialite´s Digestives, Pavillon Hbis, Place d’Arsonval, 69437 Lyon cedex 03, France, 2Universite´ de Lyon, Universite´ Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, 3Hospices Civils de Lyon, Hoˆpital Edouard Herriot, Service d’Anatomie et Cytologie Pathologiques, 69437 Lyon cedex 03, France, 4Hospices Civils de Lyon, Hoˆpital Edouard Herriot, Service de Ge´ne´tique Mole´culaire, 69437 Lyon cedex 03, France, 5INSERM, UMR 1052, Faculte´ Laennec, Lyon Cancer Research Center, 69372 Lyon cedex 08, France, 6Hospices Civils de Lyon, Groupement Hospitalier Est, Fe´de´ration d’Endocrinologie, 59 Boulevard Pinel, 69677 Bron cedex, France and 7Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Endocrinologie, Chemin du Grand Revoyet, 69310 Pierre Be´nite, France (Correspondence should be addressed to C Lombard-Bohas at Hospices Civils de Lyon, Hoˆpital Edouard Herriot, Fe´de´ration des Spe´cialite´s Digestives; Email: [email protected]) Abstract Ten percent of paragangliomas are malignant and one-third occurs in a genetic background. We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria). Tumor cells harbored a new mutation in SDHB gene and showed aberrant hypermethylation of O6-methylguanine-DNA-methyltransferase promoter. Our report suggests the importance of molecular predictive factors of response for the selection of chemotherapeutic as well as targeted agents. This observation points to a possible genotype response to treatment relationships, which could help to design tailor-made treatments in the future. European Journal of Endocrinology 166 1107–1111 Case report in the tumor (mouse anti-MGMT MAB, clone MT23.2, Invitrogen Corporation) with positive staining in lym- In 1991, a 39-year-old man had a simultaneous phoid cells as internal positive control (Fig. 1). In our diagnosis of retroperitoneal paraganglioma, treated by technical conditions, no staining was observed for radical surgery, and macroprolactinoma, treated by succinate dehydrogenase subunit B (SDHB; rabbit anti- transphenoidal surgery, dopaminergic agonists, and SDHB polyclonal antibody HPA002868, Sigma–Aldrich radiotherapy. There was no family history suggestive Corporation) with positive staining in lymphoid cells as of hereditary endocrine neoplasia including pheochro- internal positive control (Fig. 2A), while staining was mocytoma, paraganglioma, medullary thyroid cancer, positive in normal adrenal cells, as a control (Fig. 2B). cutaneous lesions, or other endocrine tumor. SDHB gene mutational analyses demonstrated a novel In April 2009, 18 years later, at the age of 57, the germline mutation c.412G/A, p.Asp138Asn in exon 4. patient was referred for dyspnea and poor performance Aberrant hypermethylation of MGMT promoter was status (Eastern Cooperative Oncology Group Per- revealed by methylation-specific PCR assay performed on formance Status (ECOG) PSZ3). Computed tomography bisulfite-treated DNA. scan showed bilateral mediastinal lymph nodes with The patient was successively treated by gemcitabine tracheal compression associated with two basithoracic and oxaliplatin (GEMOX), sunitinib, and temozolomide– lung nodules. Serum chromogranin A levels were capecitabine, using doses previously suggested for 2550 mg/l. Urinary and plasmatic catecholamines were neuroendocrine tumors (NETs) (1, 2, 3). Clinical res- within normal limits. Metaiodobenzylguanidine (MIBG) ponse (improvement of dyspnea, voice, and fatigue), showed low activity inside the left hilar lymph nodes. In biological response (serum chromogranin A levels), and contrast, the 18FDG-PET scan showed high-grade radiological response (using RECIST criteria) are activity in mediastinal and lung metastases. The reported in Fig. 3. First, the patient received eight cycles histological and immunohistochemical examinations of of gemcitabine (1000 mg/m2 i.v.) combined with a mediastinal lymph node biopsy concluded to a oxaliplatin (100 mg/m2 i.v.) every 14 days; he presented metastatic paraganglioma. Ki67 index (MIB-1; Dako, with dramatic clinical improvement after three cycles Glostrup, Denmark) was 30%. No staining was observed (ECOG PSZ0), but with grade 2 paresthesia after eight for O6-methylguanine-DNA-methyltransferase (MGMT) cycles, and partial response rate (17%) using RECIST q 2012 European Society of Endocrinology DOI: 10.1530/EJE-11-1098 Online version via www.eje-online.org Downloaded from Bioscientifica.com at 10/01/2021 04:07:30PM via free access 1108 C Nozie`res and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166 Discussion Paragangliomas are tumors that develop from extra- adrenal chromaffin cells. Approximately 10% of para- gangliomas are malignant (4, 5). Until 2002, 10% of pheochromocytoma/paraganglioma were considered to Tumor be hereditary. Three possible underlying genetic disorders were identified: multiple endocrine neoplasia type 2 (MEN2), Von–Hippel Lindau (VHL) disease, and neurofibromatose type 1 (NF1). In 2000, mutations in the genes encoding the mitochondrial complex enzyme SDH were discovered (6) and the rate of mutation detection in paragangliomas reached 25–30% (4, 5, 7). New algorithms of genetic testing have been proposed depending on the family/sporadic context, localization of the primary tumor, evidence for bilateral occurrence, Figure 1 MGMT immunohistochemistry: tumor of the patient biochemical profile of catecholamine secretion, and negative for MGMT with positive staining in lymphoid cells as malignant presentation (4, 8). SDHB mutations were internal positive control. Original magnification !40. Full colour associated with the risk of malignancy and poor prognosis version of this figure available via http://dx.doi.org/10.1530/EJE-11- (4, 9), but in contrast with our case, not with tumor 1098. response to chemotherapy in preliminary data (10).In our case, SDHB gene was first sequenced because of criteria. Two months after the end of GEMOX, clinical recurrence of malignant paraganglioma, in a context of and radiological progression occurred. Then, sunitinib negative family history and absence of catecholamine (37.5 mg p.o., once daily) was started but stopped after secretion. Indeed, in those patientswith malignant disease 1 month due to the occurrence of severe hemoptysis secondary to an extra-adrenal paraganglioma, almost treated by arterial embolization; tumor response was 50% had SDHB mutations (11). A novel germline not assessed at this time. Lastly, he received eight mutation, c.412G/A, p. Asp138Asn in exon 4, was cycles of capecitabine (750 mg/m2 p.o., twice daily, days 2 identified in our patient. The functional consequences of 1–14) and temozolomide (200 mg/m p.o., once daily, this mutation were explored by immunostaining of the days 10–14) every 28 days; filgrastim was given to protein. Loss of expression of SDHB protein was an prevent neutropenia (once daily, days 5–10 after each argument for the loss of wild-type SDHB allele in the cycle); dramatic objective response rate (70% with tumor, a mechanism already involved in SDHB-related RECIST criteria) occurred. The duration of response was tumors (12, 13). 8 months, but capecitabine–temozolomide failed to Surgical resection is considered as the primary undergo a new disease control at the time of tumor treatment when possible. Currently, there is no curative progression. External radiotherapy of the mediastinum treatment for unresectable malignant paraganglioma. is ongoing. Established treatment modalities include surgery and radionucleotide treatment. Chemotherapy is proposed in patients with rapidly progressing tumors and negative MIBG scintigraphy. The optimal systemic treatment for advanced disease is not assessed, due in part to the lack of agents with proven efficacy. The most used regimen combines cyclophosphamide, vincristine, and dacarbazine (CVD) and can provide tumor regression up to 50% (14). Other regimens have been tested, including gemcitabine alone or with docetaxel (15, 16) or paclitaxel (17) and etoposide–cisplatin (18); however, treatment experience with all these regimens is limited and toxicities are severe, whereas quality of life is an important objective in patients whose survival ABmay be long. Sunitinib appears to be a promising treatment in this malignancy based on a few case Figure 2 SDHB immunohistochemistry: tumor of the patient reports (19, 20). The mechanism of action is similar to negative for SDHB with positive staining in lymphoid cells as internal that described in other hypoxia-driven tumors and positive control (A); striking positive cytoplasmic staining of adrenal cells, as a control (B). Original magnification !10 (inset !20). Full phase II trials are underway (www.clinicaltrials.gov: colour version of this figure available via http://dx.doi.org/10.1530/ NCT00843037 and NCT01371201). The other oral EJE-11-1098. drug experiencing some efficacy in this malignancy is www.eje-online.org Downloaded from Bioscientifica.com at 10/01/2021 04:07:30PM via free access EUROPEAN
Load more

Recommended publications
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: from Biology to Therapy
    International Journal of Molecular Sciences Review Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy 1, 1, 1,2,3, 3,4 María San Román Gil y, Javier Pozas y, Javier Molina-Cerrillo * , Joaquín Gómez , Héctor Pian 3,5, Miguel Pozas 1, Alfredo Carrato 1,2,3 , Enrique Grande 6 and Teresa Alonso-Gordoa 1,2,3 1 Medical Oncology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] (M.S.R.G.); [email protected] (J.P.); [email protected] (M.P.); [email protected] (A.C.); [email protected] (T.A.-G.) 2 The Ramon y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, Spain 3 Medicine School, Alcalá University, 28805 Madrid, Spain; [email protected] (J.G.); [email protected] (H.P.) 4 General Surgery Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain 5 Pathology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain 6 Medical Oncology Department, MD Anderson Cancer Center, 28033 Madrid, Spain; [email protected] * Correspondence: [email protected] These authors have contributed equally to this work. y Received: 30 June 2020; Accepted: 10 July 2020; Published: 13 July 2020 Abstract: Thyroid cancer represents a heterogenous disease whose incidence has increased in the last decades. Although three main different subtypes have been described, molecular characterization is progressively being included in the diagnostic and therapeutic algorithm of these patients. In fact, thyroid cancer is a landmark in the oncological approach to solid tumors as it harbors key genetic alterations driving tumor progression that have been demonstrated to be potential actionable targets.
    [Show full text]
  • Updates on the Genetics of Neuroendocrine Tumors
    Updates on the Genetics of Neuroendocrine Tumors NET Patient Conference March 8, 2019 Anna Raper, MS, CGC Division of Translational Medicine and Human Genetics No disclosures 2 3 Overview 1. Cancer/tumor genetics 2. Genetics of neuroendocrine tumors sciencemag.org 4 The Genetics of Cancers and Tumors Hereditary v. Familial v. Sporadic Germline v. somatic genetics Risk When to suspect hereditary susceptibility 5 Cancer Distribution - General Hereditary (5-10%) • Specific gene variant is inherited in family • Associated with increased tumor/cancer risk Familial (10-20%) • Multiple genes and environmental factors may be involved • Some increased tumor/cancer risk Sporadic • Occurs by chance, or related to environmental factors • General population tumor/cancer risk 6 What are genes again? 7 Normal gene Pathogenic gene variant (“mutation”) kintalk.org 8 Cancer is a genetic disease kintalk.org 9 Germline v. Somatic gene mutations 10 Hereditary susceptibility to cancer Germline mutations Depending on the gene, increased risk for certain tumor/cancer types Does not mean an individual WILL develop cancer, but could change screening and management recommendations National Cancer Institute 11 Features that raise suspicion for hereditary condition Specific tumor types Early ages of diagnosis compared to the general population Multiple or bilateral (affecting both sides) tumors Family history • Clustering of certain tumor types • Multiple generations affected • Multiple siblings affected 12 When is genetic testing offered? A hereditary
    [Show full text]
  • Classification and General Considerations of Thyroid Cancer
    Central Annals of Clinical Pathology Review Article *Corresponding author Hiroshi Katoh, Department of Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Classification and General Sagamihara, 252-0374, Japan, Tel: 81-42-778-8735; Fax:81-42-778-9556; Email: Submitted: 22 December 2014 Considerations of Thyroid Accepted: 12 March 2015 Published: 13 March 2015 Cancer ISSN: 2373-9282 Copyright Hiroshi Katoh*, Keishi Yamashita, Takumo Enomoto and © 2015 Katoh et al. Masahiko Watanabe OPEN ACCESS Department of Surgery, Kitasato University School of Medicine, Japan Keywords Abstract • Thyroid cancer • Pathological classification Thyroid cancer is the most common malignancy in endocrine system, composed of • Genetic alteration four major types; papillary thyroid carcinoma, follicular thyroid carcinoma, anaplastic thyroid carcinoma, and medullary thyroid carcinoma. The incidence of thyroid cancer, especially differentiated thyroid cancer, is increasing in developed countries. Growing body of studies on molecular pathogenesis in thyroid cancer provide clues for further research and diagnostic/therapeutic targets. The general pathological classifications and clinical features of follicular cell derived thyroid carcinomas are overviewed, and recent advances of genetic alterations are discussed in this review. ABBREVIATIONS growth. PTC consists of 85-90% of all thyroid cancer cases, followed by FTC (5-10%) and MTC (about 2%). ATC accounts for PTC: Papillary Thyroid Cancer; FTC: Follicular Thyroid less than 2% of thyroid cancers and typically arises in the elder Cancer; ATC: Anaplastic Thyroid Cancer; MTC: Medullary patients. Its incidence continues to rise with age. The mechanism Thyroid Cancer; PDTC: Poorly Differentiated Thyroid Cancer; of MTC carcinogenesis is the activation of RET signaling caused DTC: Differentiated Thyroid Cancer by RET mutations [6], which are not observed in follicular INTRODUCTION thyroid cell derived cancers.
    [Show full text]
  • THYROID CANCER STRUCTURED REPORTING PROTOCOL (2Nd Edition 2020)
    THYROID CANCER STRUCTURED REPORTING PROTOCOL (2nd Edition 2020) Incorporating the: International Collaboration on Cancer Reporting (ICCR) Carcinoma of the Thyroid Dataset www.ICCR-Cancer.org Core Document versions: • ICCR dataset: Carcinoma of the Thyroid 1st edition v1.0 • AJCC Cancer Staging Manual 8th edition • World Health Organization (2017) Classification of Tumours of Endocrine Organs (4th edition). Volume 10 2 Structured Reporting Protocol for Thyroid Cancer 2nd edition ISBN: 978-1-76081-423-6 Publications number (SHPN): (CI) 200280 Online copyright © RCPA 2020 This work (Protocol) is copyright. You may download, display, print and reproduce the Protocol for your personal, non-commercial use or use within your organisation subject to the following terms and conditions: 1. The Protocol may not be copied, reproduced, communicated or displayed, in whole or in part, for profit or commercial gain. 2. Any copy, reproduction or communication must include this RCPA copyright notice in full. 3. With the exception of Chapter 6 - the checklist, no changes may be made to the wording of the Protocol including any Standards, Guidelines, commentary, tables or diagrams. Excerpts from the Protocol may be used in support of the checklist. References and acknowledgments must be maintained in any reproduction or copy in full or part of the Protocol. 4. In regard to Chapter 6 of the Protocol - the checklist: • The wording of the Standards may not be altered in any way and must be included as part of the checklist. • Guidelines are optional and those which are deemed not applicable may be removed. • Numbering of Standards and Guidelines must be retained in the checklist, but can be reduced in size, moved to the end of the checklist item or greyed out or other means to minimise the visual impact.
    [Show full text]
  • Primary Pancreatic Paraganglioma: a Case Report and Literature Review Shengrong Lin1, Long Peng1, Song Huang2, Yong Li1 and Weidong Xiao1*
    Lin et al. World Journal of Surgical Oncology (2016) 14:19 DOI 10.1186/s12957-016-0771-2 CASE REPORT Open Access Primary pancreatic paraganglioma: a case report and literature review Shengrong Lin1, Long Peng1, Song Huang2, Yong Li1 and Weidong Xiao1* Abstract Backgroud: Primary pancreatic paraganglioma is an extremely rare extra-adrenal paraganglioma. Case presentation: We report a case of primary pancreatic paraganglioma undergoing middle segment pancreatectomy in a 42-year-old woman. Histological examination showed that the tumor was composed of well- defined nests of cuboidal cells separated by vascular fibrous septa, forming the classic Zellballen pattern. The chief cells showed positive staining to neuron-specific enolase, chromogranin A, synaptophysin, and the chief cells were surrounded by S-100 protein-positive sustentacular cells. The patient has remained tumor free for 12 months after surgery. A brief discussion about the histopathological features, clinical behavior, and treatment of primary pancreatic paraganglioma, and review of the relevant literature is presented. Conclusions: Primary pancreatic paraganglioma is a rare clinical entity, its diagnosis mainly depends on histopathological and immunohistochemical examinations. Complete surgical resection is the first choice of treatment and close postoperative follow-up is necessnary. Keywords: Pancreas, Paraganglioma, Middle segment pancreatectomy Background function, renal function, and blood glucose were within Paragangliomas are rare neuroendocrine tumors (NETs) normal ranges. Serum levels of CEA, CA19-9, and that arise from the extra-adrenal chromaffin cells of the CA125 were normal. The level of 24-h urinary norepin- autonomic nervous system, with an average annual inci- ephrine excretion was also normal. Unenhanced com- dence rate of only 2 to 8 per 1 million adults.
    [Show full text]
  • Collecting Cancer Date: Thyroid and Adrenal Gland 2017‐2018 Naaccr Webinar Series
    6/8/2018 COLLECTING CANCER DATE: THYROID AND ADRENAL GLAND 2017‐2018 NAACCR WEBINAR SERIES Q&A • Please submit all questions concerning webinar content through the Q&A panel. • Reminder: • If you have participants watching this webinar at your site, please collect their names and emails. • We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar. 2 1 6/8/2018 Fabulous Prizes 3 AGENDA • Anatomy • Epi Moment • Grade • ICD‐O‐3 • Solid Tumor Rules (Multiple Primary and Histology Rules) • Seer Summary Stage and AJCC Staging 4 2 6/8/2018 ANATOMY AND HISTOLOGY 5 THYROID • Enodocrine gland • Anterior neck • Divided in two lobes • NOT a paired site • Sternohyoid/Sternothyroid muscles • In front of thyroid, important for Staging 6 3 6/8/2018 THYROID • Follicular cells • Thyroid hormone (thyroxine + triiodthyronine) • C cells (parafollicular cells) • Calcitonin • Lymphocytes • Stromal cells 7 TYPES OF MALIGNANT THYROID TUMORS • Papillary • Follicular • Hürthle Cell • Medullary • Sporadic vs Familial • Anaplastic 8 4 6/8/2018 ADRENAL GLAND • Endocrine glands • Above the kidneys • Epinephrine (adrenaline), and norepinephrine • Aorta and Vena Cava • Important for staging 9 ADRENAL GLAND MEDULLA • Extension of the nervous system • Produces Hormones • Epinephrine • Norepinephrine • Pheochromocytomas, Neuroblastomas 10 5 6/8/2018 ADRENAL GLAND CORTEX • Most tumors develop • Produces steroids • Cortisol, aldosterone,
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Paragangliomas of the Head and Neck: a Pictorial Essay
    Paragangliomas of the Head and Neck: A Pictorial Essay Jerry C. Lee, MD, Ajay Malhotra, MD, Henry Wang, MD, PhD, Per-Lennart Westesson, MD, PhD, DDS Division of Diagnostic and Interventional Neuroradiology Department of Imaging Sciences University of Rochester Medical Center Rochester, New York Presentation material is for education purposes only. All rights reserved. ©2007 URMC Radiology Page 1 of 25 Purpose Learn the common locations of paragangliomas of the head and neck and where they originate. Learn the common imaging findings of paragangliomas utilizing CT, MRI, and angiography. Presentation material is for education purposes only. All rights reserved. ©2007 URMC Radiology Page 2 of 25 J. Lee, MD et al Introduction Paragangliomas of the head and neck originate most commonly from the paraganglia within the carotid body, vagal nerve, middle ear, and jugular foramen. Also called glomus tumors, they arise from paraganglion cells of neuroectodermal origin frequently located near nerves and vessels. The function of most paraganglia in the head and neck is obscure; one exception is the carotid body, which is a chemoreceptor. Paragangliomas account for 0.6% of all neoplasms in the head and neck region, and about 80% of all paraganglioms are either carotid body tumors or glomus jugulare tumors. The classic manifestation of a carotid body tumor is a nontender, enlarging lateral neck mass which is mobile, pulsatile, and associated with a bruit. The jugulare and tympanicum tumors commonly cause pulsatile tinnitus and hearing loss and may cause cranial nerve compression. Vagal paraganglioms are the least common and present as a painless neck mass which may result in dysphagia and hoarseness.
    [Show full text]
  • Head and Neck Paraganglioma: Medical Assessment, Management, and Literature Update
    Journal of Otorhinolaryngology, Hearing and Balance Medicine Article Head and Neck Paraganglioma: Medical Assessment, Management, and Literature Update Nathan Hayward 1,* and Vincent Cousins 2,3 1 Registrar (Otolaryngology, Head and Neck Surgery), Melbourne 3001, Australia 2 Department of Surgery, Monash University, Melbourne 3168, Australia; [email protected] 3 ENT—Otoneurology Unit, The Alfred, Melbourne 3004, Australia * Correspondence: [email protected]; Tel.: +61-040-368-8327 Received: 8 October 2017; Accepted: 3 December 2017; Published: 8 December 2017 Abstract: Head and neck paraganglioma (HNPGL) are rare, highly vascular; typically slow growing and mostly benign neoplasms arising from paraganglia cells. HNPGL cause morbidity via mass effect on adjacent structures (particularly the cranial nerves), invasion of the skull base and, rarely, catecholamine secretion with associated systemic effects. The last decade has seen significant progress in the understanding of HNPGL genetics, with pertinent implications for diagnostic assessment and management of patients and their relatives. The implicated genes code for three of the five subunits of mitochondrial enzyme succinate dehydrogenase (SDH); recent literature reports that approximately one third of all HNPGL are associated with SDH mutations—a prevalence significantly greater than traditionally thought. There are distinct phenotypical syndromes associated with mutations in each individual SDH subunit (SDHD, SDHB, SDHC, and SDHAF2). This article focuses on the clinical features of HNPGL, the implications of HNPGL genetics, and the current evidence relating to optimal identification, investigation, and management options in HNPGL, which are supported by reference to a personal series of 60 cases. HNPGL require a systematic and thorough assessment to appropriately guide management decisions, and a suggested algorithm is presented in this article.
    [Show full text]
  • Pancreatic Paraganglioma: a Case Report and Literature Review
    pISSN 2384-1095 iMRI 2021;25:47-52 https://doi.org/10.13104/imri.2021.25.1.47 eISSN 2384-1109 Pancreatic Paraganglioma: a Case Report and Literature Review Joon Suk Park1, Seon Jeong Min1, Soo Kee Min2, Jung-Ah Choi1 1Department of Radiology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea 2Department of Pathology, Hallym University Sacred Heart Hospital, Anyang, Korea Paraganglioma is a rare tumor of paraganglia, derived from neural crest cells in sympathetic or parasympathetic ganglions. It can be widely distributed from the skull base to the bottom of the pelvis. The pancreas, however, is a rare location of this neoplasm, and only a limited number of cases have been reported in the English literature, especially with gadoxetic-acid-enhanced magnetic resonance imaging Case Report (MRI) and diffusion-weighted images (DWI). We herein report a case of pathologically proven paraganglioma in the pancreas head with a literature review on endoscopic ultrasonography (EUS), computed tomography (CT), gadoxetic-acid-enhanced MRI, and DWI sequence. Received: January 2, 2021 Revised: January 25, 2021 Accepted: February 5, 2021 Keywords: Pancreas; Paraganglioma; Computed tomography; Magnetic resonance imaging Correspondence to: Joon Suk Park, M.D. Department of Radiology, Hallym University Dongtan Sacred Heart Hospital, 7, Keunjaebong- INTRODUCTION gil, Hwaseong-si, Gyeiniggi-do 18450, Korea. Paraganglioma is a rare tumor derived from neural crest cells in sympathetic or Tel. +82-10-3993-8959 parasympathetic ganglions (1). During the development of paraganglioma, neural E-mail: parkjoonsuk8856@ crest cells get dispersed throughout the body and aggregate to form paraganglia (2). gmail.com Therefore, paragangliomas can be found in every part of the body where paraganglia are known to arise, frequently in the posterior mediastinum and thoracolumbar paravertebral region, including Zuckerkandl’s body (1).
    [Show full text]
  • Localization and Treatment of Familial Malignant Nonfunctional Paraganglioma with Iodine-131 MIBG: Report of Two Cases
    Localization and Treatment of Familial Malignant Nonfunctional Paraganglioma with Iodine-131 MIBG: Report of Two Cases F. Khafagi, J. Egerton-Vernon, T. van Doom, W. Foster, I. B. McPhee, and R. W. G. Allison Departments of Endocrinology. Nuclear Medicine, Physical Sciences, Vascular Surgery, Orthopedic Surgery and Queensland Radium Institute, Royal Brisbane Hospital, Brisbane, A itstralia Two cases of familial, malignant, nonfunctional paraganglioma are reported. Uptake of iodine- 131 metaiodobenzylguanidine ([131I]MIBG) by the tumors and métastaseswas demonstrated. In the first case, with multicentric and locally invasive disease, [131I]MIBG correctly localized a right carotid body paraganglioma which had been missed arteriographically. In the second case, with widespread, symptomatic metastatic disease, a therapeutic dose of [131I]MIBG produced palliation of bone pain after the failure of radio- and chemotherapy. Uptake of [131I] MIBG by paragangliomas does not correlate with catecholamine secretory activity, lodine-131 MIBG should be considered as a therapeutic option in unresectable, malignant paragangliomas which take up this radiopharmaceutical. J NucíMed 28:528-531,1987 . aragangliomas are tumors arising from extra-adre found a place in localization not only of pheochromo nal paraganglion tissue, an extensive, multicentric sys cytomas but also of neuroblastomas (6), carcinoid tu tem ofhistologicallyand ultrastructurally similar organs mors (7), and medullary carcinoma of the thyroid (8). (paraganglia). Paraganglia can be shown to contain It is also being used to treat malignant pheochromocy small amounts of catecholamine and are best classified toma (9) and neuroblastoma (6). More recently, uptake according to their sites of origin; they are designated of [I3II]MIBG has been reported in nonfunctional par "functional" or "nonfunctional" according to whether agangliomas (70,77).
    [Show full text]